ArticleFrontiers in oncology2020
HTRA3 Is a Prognostic Biomarker and Associated With Immune Infiltrates in Gastric Cancer.
Article in Frontiers in oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it, 24 citations in OpenAlex.
- Exploring the Role of HtrA Family Genes in Cancer: A Systematic Review.Molecular diagnosis & therapy · 2024Pooled it
- HTR3A Receptor Signaling in Human Disease: From Bioelectrical Regulation to Therapeutic Targeting.Molecular neurobiology · 2026Review
- An Interpretable Omics-to-Image Transformer Framework for Cancer Prognosis Prediction.Computational and structural biotechnology journal · 2026Article
- Machine learning based obesity and aging related signature for predicting the prognosis and immunotherapy benefit in stomach adenocarcinoma.Discover oncology · 2025Article
- CHMP6 as a novel prognostic biomarker in bladder cancer: insights from a comprehensive cell death-related gene risk model.Frontiers in oncology · 2025Article
- The relationship and clinical significance of lactylation modification in digestive system tumors.Cancer cell international · 2024Review
- Integrative analysis indicates the potential values of ANKRD53 in stomach adenocarcinoma.Discover oncology · 2024Article
- Integrating multiple machine learning algorithms for prognostic prediction of gastric cancer based on immune-related lncRNAs.Frontiers in genetics · 2023Article
- HtrA3: a promising prognostic biomarker and therapeutic target for head and neck squamous cell carcinoma.PeerJ · 2023Article
- Whole-transcriptome bioinformatics revealedJournal of Taibah University Medical Sciences · 2022Article
- Screening and Validation of a Carvacrol-Targeting Viability-Regulating Protein, SLC6A3, in Liver Hepatocellular Carcinoma.Disease markers · 2022Article
- Upregulated of ANXA3, SORL1, and Neutrophils May Be Key Factors in the Progressionof Ankylosing Spondylitis.Frontiers in immunology · 2022Article
- Integrated Analysis of miR-7-5p-Related ceRNA Network Reveals Potential Biomarkers for the Clinical Outcome of Gastric Cancer.Journal of oncology · 2022Article
- Integrated analysis of fibroblasts molecular features in papillary thyroid cancer combining single-cell and bulk RNA sequencing technology.Frontiers in endocrinology · 2022Article
- Analysis of the regulatory mechanisms of prognostic immune factors in thyroid cancer.Frontiers in oncology · 2022Article
- Integrative Single-Cell RNA-Seq and ATAC-Seq Analysis of Mesenchymal Stem/Stromal Cells Derived from Human Placenta.Frontiers in cell and developmental biology · 2022Article
- Immune infiltration profiling in gastric cancer and their clinical implications.Cancer science · 2021Article
- DAP10 Predicted the Outcome of Pediatric B-Cell Acute Lymphoblastic Leukemia and Was Associated with the T-Cell Exhaustion.Journal of oncology · 2021Article
- Identification of an M1 Macrophages-Related Signature for Predicting the Survival and Therapeutic Response in Gastric Cancer.IET systems biologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
HtrA serine peptidase 3 (HTRA3) participates in multiple signal pathways and plays an important regulatory role in various malignancies; however, its role on prognosis and immune infiltrates in gastric cancer (GC) remains unclear. The study investigated HTRA3 expression in tumor tissues and its association with immune infiltrates, and determined its prognostic roles in GC patients. Patients with GC were collected from the cancer genome atlas (TCGA). We compared the expression of HTRA3 in GC and normal gastric mucosa tissues with Wilcoxon rank sum test. And logistic regression was used to evaluate the relationship between HTRA3 and clinicopathological characters. Gene ontology (GO) term analysis, Gene set enrichment analysis (GSEA), and single-sample Gene Set Enrichment Analysis (ssGSEA) was conducted to explain the enrichmental pathways and functions and quantify the extent of immune cells infiltration for HTRA3. Kaplan-Meier analysis and Cox regression were performed to evaluate the correlation between HTRA3 and survival rates. A nomogram, based on Cox multivariate analysis, was used to predict the impact of HTRA3 on prognosis. High HTRA3 expression was significantly correlated with tumor histological type, histological grade, clinical stage, T stage, and TP53 status (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.